Literature DB >> 9180140

Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function.

A Baruch1, M Hartmann, S Zrihan-Licht, S Greenstein, M Burstein, I Keydar, M Weiss, N Smorodinsky, D H Wreschner.   

Abstract

The human MUC1 gene expresses at least 2 type 1 membrane proteins: MUC1/REP, a polymorphic high m.w. MUC1 glycoprotein often highly expressed in breast cancer tissues and containing a variable number of tandem 20 amino acid repeat units, and the MUC1/Y protein, which lacks this repeat array and, therefore, is not polymorphic. Despite their documented importance in signal transduction processes, the relative expression of the 2 isoforms in epithelial tumors is unknown. Using antibody reagents which recognize different MUC1 domains, the expression of these isoforms in malignant epithelial cells has been evaluated. A comparison of the amounts of the 2 isoforms revealed preferential expression of the novel MUC1/Y protein in breast cancer tissue samples. Furthermore, although the MUC1/REP protein is almost undetectable in HeLa cervical adenocarcinoma epithelial cells, the MUC1/Y isoform is extensively expressed in these cells. The presence of the MUC1/Y sequence as well as that of an additional tandem-repeat-array-lacking isoform, designated MUC1/X, were demonstrated by reverse transcriptase PCR amplification of RNA extracted from HeLa and ovarian carcinoma cells. It has been shown previously that the MUC1 cytoplasmic domain interacts with the SH2 domain containing GRB2 protein, which transduces signals to ras, a protein which in its activated form can lead to cell transformation. We present here data demonstrating that MUC1/Y isoform expression increases the tumorigenic potential of DA3 mouse mammary epithelial cells; in contrast, potentiation of tumorigenicity is not observed with MUC1/REP expression. Our studies thus demonstrate that expression of the MUC1 gene in epithelial tumors can give rise to substantial levels of MUC1 proteins devoid of the tandem repeat array, which are generated by alternative splicing mechanisms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9180140     DOI: 10.1002/(sici)1097-0215(19970529)71:5<741::aid-ijc9>3.0.co;2-r

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

Review 1.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

2.  Transmembrane mucins as novel therapeutic targets.

Authors:  Pamela E Constantinou; Brian P Danysh; Neeraja Dharmaraj; Daniel D Carson
Journal:  Expert Rev Endocrinol Metab       Date:  2011-11

Review 3.  Genetic variants of mucins: unexplored conundrum.

Authors:  Sushil Kumar; Eric Cruz; Suhasini Joshi; Asish Patel; Rahat Jahan; Surinder K Batra; Maneesh Jain
Journal:  Carcinogenesis       Date:  2017-07-01       Impact factor: 4.944

4.  C-terminal domain of rodent intestinal mucin Muc3 is proteolytically cleaved in the endoplasmic reticulum to generate extracellular and membrane components.

Authors:  Rongquan Wang; Ismat A Khatri; Janet F Forstner
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

5.  Autophagy is decreased in triple-negative breast carcinoma involving likely the MUC1-EGFR-NEU1 signalling pathway.

Authors:  Christian Garbar; Corinne Mascaux; Jérôme Giustiniani; Stéphanie Salesse; Laurent Debelle; Frank Antonicelli; Yacine Merrouche; Armand Bensussan
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms.

Authors:  Heather C Workman; Colleen Sweeney; Kermit L Carraway
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

7.  Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms.

Authors:  Lixin Zhang; Anda Vlad; Christine Milcarek; Olivera J Finn
Journal:  Cancer Immunol Immunother       Date:  2012-09-02       Impact factor: 6.968

Review 8.  MUC1: a multifaceted oncoprotein with a key role in cancer progression.

Authors:  Sritama Nath; Pinku Mukherjee
Journal:  Trends Mol Med       Date:  2014-03-22       Impact factor: 11.951

Review 9.  MUC1 in carcinoma-host interactions.

Authors:  K Denda-Nagai; T Irimura
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 3.009

Review 10.  MUC1, the renaissance molecule.

Authors:  S J Gendler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.